Idiopathic Pulmonary Fibrosis (IPF) Clinical Trial
Official title:
Short-term Effects of Supplemental Oxygen During Walking in Hypoxemic Patients With Idiopathic Pulmonary Fibrosis
Although exercise-induced desaturation is frequently observed in patients with idiopathic
pulmonary fibrosis (IPF) short-term effects of supplemental oxygen during walking have not
been investigated yet. Given, that walking ability is the most important activity of daily
life, the aim of our study is to investigate the effects of supplemental oxygen on endurance
walking capacity in hypoxemic IPF patients. In this study patients will perform 3 endurance
shuttle walk tests (ESWTs) at 85% of their individual peak performance using medical air
(=compressed room air, 2 liters/minute), 2 liters/minute oxygen, 4 liters/minute Oxygen in a
double-blinded fashion and random order.
Since there are only limited pharmacological treatment options for IPF patients, this study
may help to provide novel information about the short-term effects of supplemental oxygen.
Furthermore it may help to investigate possibilities to optimize oxygen therapy in order to
facilitate patients´ participation in activities of daily life and not at least to improve
patients´ quality of life.
Rationale:
Exercise-induced desaturation is frequently observed in patients with idiopathic pulmonary
fibrosis and predicts poorer outcomes. However, prospective studies with larger sample sizes
and those investigating the effect of oxygen on endurance time, oxygen saturation and
breathing frequency during walking are lacking. Given that walking is the most important
activity of daily life to preserve the maintenance and to participate in social life, we aim
to investigate the effects of supplemental oxygen during walking in IPF patients.
The endurance shuttle walk test (ESWT) is a well validated test with high reliability and
validity for measuring endurance walking capacity in patients with chronic obstructive
pulmonary disease (COPD). The advantage of this test in contrast to the 6-minute walk test is
that the ESWT is performed at 85% of the individual maximum that is close to the intensity of
typical daily activities. Additionally, by using the ESWT it is possible to determine the
maximum duration of exercise and to compare values at isotime (= time point when the shortest
of the 3 ESWTs ends), whereas values at the end of different six-minute walk tests (6MWTs)
are not comparable in case of different distances.
Aim:
To investigate the short-term effects of supplemental oxygen on endurance capacity during
walking (ESWT) in patients with idiopathic pulmonary fibrosis.
Design:
This study is a randomized, controlled, double-blinded cross-over trial. Following an initial
incremental shuttle walk test (ISWT) in order to determine the individual maximum walking
capacity, patients will perform 3 endurance shuttle walk tests (ESWT) at 85% of the maximal
pace. In randomized order, patients will complete one ESWT on 2l/min oxygen, one on 4l/min
oxygen and one on medical air (=compressed room air), whereas the patients as well as the
investigator will be blinded to the gas mixture provided. All 3 conditions will be provided
via nasal cannula. The time between the two ESWTs will be 24 hours in order to give enough
time for regeneration. Endurance Walking capacity as measured by the ESWT will be used as the
primary outcome.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04497831 -
Morphine for Dyspnea in Pulmonary Fibrosis
|
Phase 3 | |
Recruiting |
NCT05119972 -
Tolerability, Pharmacokinetics and Efficacy of ZSP1603 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 1/Phase 2 | |
Completed |
NCT01718990 -
Biomarker Discovery for Novel Drug Development in Idiopathic Pulmonary Fibrosis
|
||
Completed |
NCT00162760 -
Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide
|
Phase 2 | |
Terminated |
NCT04589260 -
TD-1058 First-In-Human Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis
|
Phase 1 | |
Completed |
NCT04069143 -
A Study to Evaluate the Safety, Tolerability, Kinetics and Repeatability of 18F-BMS-986327
|
Phase 1 | |
Terminated |
NCT02013700 -
Allogeneic Human Cells (hMSC)in Patients With Idiopathic Pulmonary Fibrosis Via Intravenous Delivery (AETHER)
|
Phase 1 | |
Active, not recruiting |
NCT04598919 -
Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis
|
Phase 1/Phase 2 | |
Completed |
NCT03981094 -
A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy Participants
|
Phase 1 | |
Completed |
NCT02758808 -
Pulmonary Fibrosis Foundation Patient Registry
|
||
Not yet recruiting |
NCT05387785 -
Study to Assess the Safety and Tolerability of ANG-3070 in Subjects With Idiopathic Pulmonary Fibrosis
|
Phase 1 | |
Active, not recruiting |
NCT05938920 -
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 2 | |
Completed |
NCT02538536 -
A Phase 2 Study to Evaluate the Safety and Tolerability of PBI-4050 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 2 | |
Completed |
NCT01371305 -
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 2 | |
Withdrawn |
NCT03720483 -
Inhaled NAC in Treatment of IPF
|
Phase 1/Phase 2 | |
Recruiting |
NCT03478553 -
The Genetics of Pulmonary Fibrosis
|
||
Recruiting |
NCT05975983 -
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
Completed |
NCT03650075 -
To Determine Safety and Tolerability of MG-S-2525 and to Evaluate Its PK Profile in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT03832946 -
A Study to Test the Efficacy and Safety of Inhaled GB0139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 2 | |
Completed |
NCT02874989 -
Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial
|
Phase 1 |